{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T03:14:27Z","timestamp":1761016467043,"version":"build-2065373602"},"reference-count":12,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,17]],"date-time":"2013-07-17T00:00:00Z","timestamp":1374019200000},"content-version":"vor","delay-in-days":2785,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2005,12]]},"DOI":"10.1016\/j.seizure.2005.09.003","type":"journal-article","created":{"date-parts":[[2005,11,9]],"date-time":"2005-11-09T07:15:50Z","timestamp":1131520550000},"page":"577-585","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Long-term efficacy of levetiracetam for partial seizures"],"prefix":"10.1016","volume":"14","author":[{"given":"Bassel","family":"Abou-Khalil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynn","family":"Schaich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2005.09.003_bib1","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1592\/phco.21.17.1375.34432","article-title":"Levetiracetam: a novel antiepileptic drug","volume":"21","author":"Hovinga","year":"2001","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.seizure.2005.09.003_bib2","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1345\/aph.1A032","article-title":"Levetiracetam: a different approach to the pharmacotherapy of epilepsy","volume":"36","author":"Welty","year":"2002","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.seizure.2005.09.003_bib3","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1528-1157.2000.tb04605.x","article-title":"Efficacy and tolerability of levetiracetam 3000mg\/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy","volume":"41","author":"Ben-Menachem","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2005.09.003_bib4","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1212\/WNL.55.2.236","article-title":"Levetiracetam for partial seizures. Results of a double-blind, randomized clinical trial","volume":"55","author":"Cereghino","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2005.09.003_bib5","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1528-1157.2000.tb00323.x","article-title":"Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures","volume":"41","author":"Shorvon","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2005.09.003_bib6","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1053\/seiz.2000.0380","article-title":"A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000mg daily and 4000mg daily, without titration in patients with refractory epilepsy","volume":"9","author":"Betts","year":"2000","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2005.09.003_bib7","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1059-1311(02)00292-3","article-title":"An open-label study of levetiracetam at individualised doses between 1000 and 3000mgday\u22121 in adult patients with refractory epilepsy","volume":"12","author":"Abou-Khalil","year":"2003","journal-title":"Seizure"},{"year":"1993","series-title":"Coding symbols for thesaurus of adverse reaction terms","key":"10.1016\/j.seizure.2005.09.003_bib8"},{"key":"10.1016\/j.seizure.2005.09.003_bib9","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1528-1157.1989.tb05316.x","article-title":"Proposal for revised classification of epilepsies and epileptic syndromes","volume":"30","year":"1989","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2005.09.003_bib10","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0920-1211(02)00247-4","article-title":"Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy","volume":"53","author":"Ben-Menachem","year":"2003","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2005.09.003_bib11","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S1059-1311(02)00251-0","article-title":"Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy","volume":"12","author":"Ben-Menachem","year":"2003","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2005.09.003_bib12","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S0090-9556(24)15285-3","article-title":"In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic drug","volume":"27","author":"Nicolas","year":"1999","journal-title":"Drug Metab Dispos"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131105001627?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131105001627?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:34:21Z","timestamp":1761010461000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131105001627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12]]},"references-count":12,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["S1059131105001627"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2005.09.003","relation":{},"ISSN":["1059-1311"],"issn-type":[{"type":"print","value":"1059-1311"}],"subject":[],"published":{"date-parts":[[2005,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term efficacy of levetiracetam for partial seizures","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2005.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}